论文部分内容阅读
入选40例T2DM患者按1:1比例随机分为甘精胰岛素联合二甲双胍(甘精组)20例和预混胰岛素(预混组)20例。两组的基线情况无统计学意义(P>0.05)。结果治疗12周后,两组的HbAlc及FBG较治疗前均有显著下降(P<0.05)。两组间在HbAlc下降幅度、体重增加、胰岛素剂量均有统计学意义(P<0.05)。低血糖发生率的差异有统计学意义(P<0.05)。结论两组都可以达到良好的血糖控制,而甘精胰岛素联合二甲双胍更具有其有效性和安全性。
Forty patients with T2DM were randomized into 1: 1 ratio of 20 patients with insulin glargine combined with metformin (Gangen group) and 20 patients with premixed insulin (premixed group). There was no significant difference in baseline between the two groups (P> 0.05). Results After 12 weeks of treatment, HbA1c and FBG in both groups were significantly lower than those before treatment (P <0.05). The decrease of HbAlc, weight gain and insulin dosage had statistical significance between the two groups (P <0.05). The incidence of hypoglycemia was significantly different (P <0.05). Conclusion Both groups can achieve good glycemic control, and Glargine and metformin are more effective and safe.